subscribeSubscribe
Cayman Chemical Receives CEP for Latanoprost API from EDQM

Cayman Chemical Receives CEP for Latanoprost API from EDQM
CPHI-ONLINE
18 Oct 2023
Share Share
Thea Pharma Inc. Launches IYUZEH 0.005% in the U.S.

Thea Pharma Inc. Launches IYUZEH 0.005% in the U.S.
PR NEWSWIRE
26 Sep 2023
Share Share
IYUZEH Demonstrated Similar IOP Lowering Efficacy when Compared to Xalatan

IYUZEH Demonstrated Similar IOP Lowering Efficacy when Compared to Xalatan
PR NEWSWIRE
03 Mar 2023
Share Share
Thea gets FDA nod for preservative-free rival to Viatris drug

Thea gets FDA nod for preservative-free rival to Viatris drug
Nick Paul Taylor FIERCEPHARMA
20 Dec 2022
Share Share
Thea Pharma Announces FDA Approval of IYUZEH for Reduction of IOP

Thea Pharma Announces FDA Approval of IYUZEH for Reduction of IOP
BUSINESSWIRE
15 Dec 2022
Share Share
Alcon Completes Acquisition of Aerie Pharmaceuticals

Alcon Completes Acquisition of Aerie Pharmaceuticals
BUSINESSWIRE
22 Nov 2022
Share Share
TearClear Announces Positive Topline Results from CLEAR Phase 3 Study

TearClear Announces Positive Topline Results from CLEAR Phase 3 Study
GLOBENEWSWIRE
29 Sep 2022
Share Share
Aerie Announces 1st Participant Dosed in COMET-3 Study of AR-15512

Aerie Announces 1st Participant Dosed in COMET-3 Study of AR-15512
BUSINESSWIRE
01 Aug 2022
Share Share
FDA Confirms Paragraph IV Patent Litigation for Latanoprost & Neutarsudil Dimesylate

FDA Confirms Paragraph IV Patent Litigation for Latanoprost & Neutarsudil Dimesylate
FDA
08 Feb 2022
Share Share
TearClear successfully initiates of TC-002 Latanoprost Ophthalmic Solution

TearClear successfully initiates of TC-002 Latanoprost Ophthalmic Solution
GLOBENEWSWIRE
07 Feb 2022
Share Share